02:39 AM EST, 11/05/2026 (MT Newswires) -- Hikma Pharmaceuticals (HIK.L) made adjustments to its group operating profit guidance for full-year 2026 with its latest trading update. The London-listed drugmaker said Thursday it expects group operating profit to be in the range of $740 million to $760 million, compared with its previous forecast of between $720 million and $770 million. However, the company continues to expect group revenue growth of between 2% and 4% for the year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.